Phase 2 trial of long-term outcomes with bevacizumab and chemoradiation for locoregionally advanced nasopharyngeal carcinoma

A multicenter phase 2 nonrandomized controlled trial evaluated long-term toxic effects and clinical outcomes with bevacizumab plus standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma. The combination was not associated with excessive or unwarranted toxic effects. The 5- and 7-year rates were 79.5% and 69.7% for overall survival, 61.2% and 56.3% for progression-free survival, 74.9% and 72.3% for local-regional progression-free interval, and 79.5% and 79.5% for distant metastasis-free interval.